Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
about
Prevention of Hepatitis B reactivation in the setting of immunosuppressionRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsRegulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction PathwayPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedHepatitis C virus reactivation in cancer patients in the era of targeted therapies.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.Imatinib-induced immune hepatitis: case report and literature review.Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.Hepatitis B reactivation in patients receiving targeted therapies.Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors.[Guidelines for vaccination of immunocompromised individuals].Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Reactivation of chronic hepatitis B infection related to imatinib mesylate therapyHepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report.Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.Is HBV prophylaxis required during CLL treatment with ibrutinib?Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
P2860
Q26747023-DDB7C183-7491-4761-8A1D-E1245E7422D2Q26851417-FF79511F-EB43-48F1-92D5-DF628A9740BFQ27481454-63CFEFE8-0403-47F9-B473-9FB6F76A1BC9Q28070090-ADCD9F4F-A332-467C-907B-7287010070C5Q28076703-A418F7F0-2019-4B33-AADF-5BA0AC31FC92Q33735212-506CB738-0EE6-43BC-9717-0277C560801DQ34397738-BBC9EF9B-E744-4560-900C-9563B536E6BFQ35037621-CE512292-F397-4E08-ADBC-4DA6096EA067Q35567748-D44973BD-D06B-422B-AD44-784A3B461467Q36654518-F280F0FE-0E66-42E0-85E7-151E84EBE7A9Q36761730-7E44C739-E80F-43A8-AED7-2B8703D53A63Q38755178-3B48D1EB-47E2-4ECB-B076-6719113CC1E7Q38810735-5D22B49A-5FC4-4B27-9F8E-44F53DF76CAFQ38996149-C108B6F3-5793-4FC1-B1EF-0E73067347FAQ39293427-761CD768-A08F-4477-8146-ACE59D2629D6Q39636564-BC9795C6-E9D9-4AD0-BEE1-1E0AE5FFE777Q40568236-FB05A72D-A442-45E1-B345-9295A93163C0Q40600058-3411D885-B9FD-489B-A746-F8DE79D454C0Q41356321-DB341624-86DB-4691-B926-9199814FB59AQ41892625-9E0B877A-57DD-4955-A0FA-0E6039DCD542Q41896329-7EBB4778-32AB-44EC-AA59-70ECFB8EE22BQ42276725-D1CF4B1B-3D46-4692-AF8B-3C4C4A81E86EQ44630703-2B973E8E-362E-41DA-95CA-4610585EB0FBQ46183882-34F26144-48A0-4D37-B865-A58918552FBCQ54653633-F31819BA-EF39-40E0-9157-8E6C172F4A33Q55007608-E2EF6E20-F18F-4DA8-B1AA-657DD4ED00A8
P2860
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@en
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@nl
type
label
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@en
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@nl
prefLabel
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@en
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@nl
P2093
P2860
P921
P1433
P1476
Fatal hepatitis B virus reacti ...... g imatinib mesylate treatment.
@en
P2093
Maruyama Y
Nakamura A
P2860
P304
P356
10.1080/14639230500236818
P577
2006-01-01T00:00:00Z